[go: up one dir, main page]

MXPA03007678A - Composicion farmaceutica oral de proxetil cefpodoxima. - Google Patents

Composicion farmaceutica oral de proxetil cefpodoxima.

Info

Publication number
MXPA03007678A
MXPA03007678A MXPA03007678A MXPA03007678A MXPA03007678A MX PA03007678 A MXPA03007678 A MX PA03007678A MX PA03007678 A MXPA03007678 A MX PA03007678A MX PA03007678 A MXPA03007678 A MX PA03007678A MX PA03007678 A MXPA03007678 A MX PA03007678A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
cefpodoxime proxetil
oral pharmaceutical
proxetil
cefpodoxime
Prior art date
Application number
MXPA03007678A
Other languages
English (en)
Inventor
Rajiv Malik
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11097036&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA03007678(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of MXPA03007678A publication Critical patent/MXPA03007678A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se relaciona a una composicion farmaceutica estable de proxetil cefpodoxima, para administracion oral.
MXPA03007678A 2001-02-27 2002-02-27 Composicion farmaceutica oral de proxetil cefpodoxima. MXPA03007678A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN190DE2001 2001-02-27
PCT/IB2002/000602 WO2002067943A1 (en) 2001-02-27 2002-02-27 Oral pharmaceutical composition of cefpodoxime proxetil

Publications (1)

Publication Number Publication Date
MXPA03007678A true MXPA03007678A (es) 2004-03-16

Family

ID=11097036

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03007678A MXPA03007678A (es) 2001-02-27 2002-02-27 Composicion farmaceutica oral de proxetil cefpodoxima.

Country Status (14)

Country Link
EP (1) EP1365764B1 (es)
JP (1) JP2004522782A (es)
KR (1) KR20030087009A (es)
CN (1) CN1505515A (es)
AT (1) ATE303149T1 (es)
AU (1) AU2002237462B2 (es)
BR (1) BR0207640A (es)
DE (1) DE60205870T2 (es)
EA (1) EA006974B1 (es)
ES (1) ES2248521T3 (es)
MX (1) MXPA03007678A (es)
NZ (1) NZ527867A (es)
OA (1) OA12687A (es)
WO (1) WO2002067943A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6766376B2 (en) 2000-09-12 2004-07-20 Sn Acquisition, L.L.C Streaming media buffering system
WO2004016251A1 (en) * 2002-08-16 2004-02-26 Orchid Chemicals And Pharmaceuticals Ltd. Sustained release pharmaceutical composition of a cephalosporin antibiotic
AU2002321743A1 (en) * 2002-08-19 2004-03-03 Orchid Health Care Sustained release pharmaceutical composition of a cephalosporin antibiotic
WO2004105728A2 (en) * 2003-05-27 2004-12-09 Ranbaxy Laboratories Limited Solid dispersions of cefpodoxime proxetil and processes for their preparation
EP1883393A2 (en) * 2005-05-05 2008-02-06 Lupin Ltd. Stabilized oral pharmaceutical compositions of cephalosporins
EA200702518A1 (ru) * 2005-05-16 2008-04-28 Элан Фарма Интернэшнл Лимитед Композиции на основе наночастиц и с контролируемым высвобождением, включающие цефалоспорин
WO2007063552A1 (en) * 2005-12-02 2007-06-07 Lupin Limited Stable taste masked formulations of cephalosporins
WO2008057058A1 (en) * 2006-11-10 2008-05-15 Nobel Ilac Sanayii Ve Ticaret As Oral pharmaceutical compositions
CN101278914B (zh) * 2008-01-02 2010-06-02 海南三叶美好制药有限公司 头孢泊肟酯干混悬剂组合物及其制备方法
TR201001417A1 (tr) * 2010-02-25 2011-09-21 Sanovel İlaç San. Ve Ti̇c. A. Ş. Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu
TR201002878A2 (tr) 2010-04-13 2011-10-21 Bi̇lgi̇ç Mahmut Sefpodoksim proksetil içeren farmasötik bileşimler.
EP2575811B1 (en) * 2010-06-03 2020-08-12 Mahmut Bilgic Pharmaceutical formulation comprising cefpodoxime proxetil and clavulanic acid
TR201007106A1 (tr) * 2010-08-25 2012-03-21 Bi̇lgi̇ç Mahmut Sefpodoksim proksetil formülasyonları.
TR201007107A1 (tr) * 2010-08-25 2012-03-21 B�Lg�� Mahmut Tat düzenleyici ajan içeren sefpodoksim proksetil formülasyonları.
TR201009168A2 (tr) * 2010-11-05 2012-05-21 Bi̇lgi̇ç Mahmut Suda dağılan sefpodoksim proksetil formülasyonları.
PT2647648T (pt) * 2010-12-03 2017-10-02 Nippon Soda Co Forma de dosagem sólida que contém uma hidroxialquil celulose de baixa viscosidade
JP6062422B2 (ja) * 2012-03-29 2017-01-18 杏林製薬株式会社 カプセル製剤
CN108175773A (zh) 2012-07-27 2018-06-19 红山生物医药有限公司 用于结肠排空的制剂和制备制剂方法
CN103142506B (zh) * 2013-04-03 2015-02-25 天津医药集团津康制药有限公司 一种头孢泊肟酯颗粒剂及其制备方法
WO2014174847A1 (ja) 2013-04-25 2014-10-30 杏林製薬株式会社 固形医薬組成物
EP2990038B1 (en) 2013-04-25 2019-11-20 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
KR101509168B1 (ko) * 2013-06-10 2015-04-06 한국화학연구원 세팔로스포린 항생제의 서방형 제제 및 이를 포함하는 서방형 약제학적 조성물
CN103301075B (zh) * 2013-06-28 2015-11-18 山东罗欣药业集团股份有限公司 一种头孢克肟组合物混悬颗粒剂及其制备方法
JP6292788B2 (ja) * 2013-07-30 2018-03-14 ライオン株式会社 錠剤及び錠剤の製造方法
JP2016204260A (ja) * 2013-10-04 2016-12-08 日本曹達株式会社 錠剤の製造方法
JP6018334B2 (ja) 2014-10-23 2016-11-02 杏林製薬株式会社 固形医薬組成物
CN104771368B (zh) * 2015-04-08 2017-12-22 石家庄四药有限公司 头孢泊肟酯速释制剂及其制备方法
CN113456599A (zh) * 2020-03-30 2021-10-01 洛阳惠中兽药有限公司 一种头孢泊肟酯片的制备方法及其制备的头孢泊肟酯片
CN113952313A (zh) * 2021-08-26 2022-01-21 宁夏医科大学 一种头孢呋辛酯胶囊及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486425A (en) * 1980-09-30 1984-12-04 Sankyo Company Limited 7-[2-(2-Aminothiazol-4-yl)-2-(syn)-methoxyiminoacetamido]-3-methoxymethyl-3-cephem-4-carboxylates
US5929086A (en) * 1996-05-10 1999-07-27 Pharmacia & Upjohn Company Topical administration of antimicrobial agents for the treatment of systemic bacterial diseases
AT500063A1 (de) * 1999-11-23 2005-10-15 Sandoz Ag Beschichtete tablettenkerne
AU2001267011B2 (en) * 2000-06-21 2006-02-02 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents

Also Published As

Publication number Publication date
ATE303149T1 (de) 2005-09-15
EP1365764B1 (en) 2005-08-31
EP1365764A4 (en) 2004-08-11
ES2248521T3 (es) 2006-03-16
DE60205870T2 (de) 2006-06-29
CN1505515A (zh) 2004-06-16
OA12687A (en) 2006-06-21
NZ527867A (en) 2004-12-24
AU2002237462B2 (en) 2006-05-18
KR20030087009A (ko) 2003-11-12
DE60205870D1 (de) 2005-10-06
EP1365764A1 (en) 2003-12-03
WO2002067943A1 (en) 2002-09-06
JP2004522782A (ja) 2004-07-29
BR0207640A (pt) 2004-07-27
EA200300937A1 (ru) 2004-04-29
EA006974B1 (ru) 2006-06-30

Similar Documents

Publication Publication Date Title
NZ527867A (en) Oral pharmaceutical composition of cefpodoxime proxetil
PL370292A1 (en) Formulations for oral administration of active compounds
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
MXPA04004674A (es) Ligados de los receptors de los canabinodies.
DZ3312A1 (fr) Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
PL364598A1 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
PL348419A1 (en) Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient
MXPA03005980A (es) Composiciones para administracion nasal de insulina.
MY142076A (en) Emulsifying systems containing azetidine derivatives
MXPA06000636A (es) Formulaciones semi-solidas para la administracion oral de taxoides.
GB2358137B (en) Compound
MXPA04004090A (es) Compuestos substituidos de 1h-quinolin-2-ona.
TW200503783A (en) Oral pharmaceutical preparation for proton pump antagonists
MXPA03006866A (es) Modificacion cristalina de depsipeptido ciclico con actividad mejorada.
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
DE60212130D1 (en) Carvedilolpolymorph
YU48200A (sh) Farmaceutski preparati
SG144141A1 (en) Semi-solid systems containing azetidine derivatives
YU83403A (sh) Korišćenje derivata piridoindolona za spravljanje lekova
WO2001095890A3 (en) Oral pharmaceutical compositions containing terbinafine
TW200407314A (en) Preparation of 4, 6-dichloro-5-fluoropyrimidine
SE9901340D0 (sv) Novel process
SE9901338D0 (sv) Novel process